FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sirgo Mark A 		2. Issuer Name and Ticker or Trading Symbol

BIODELIVERY SCIENCES INTERNATIONAL INC [ BDSI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O BIODELIVERY SCIENCES INTL, INC.,, 4131 PARKLAKE AVENUE, SUITE 225 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/14/2017
(Street)

RALEIGH, NC 27612
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   9/14/2017     S    50000   D $2.95   (1) 1509262   D    
Common Stock   9/15/2017     M    45421   A $1.78   1554683   D    
Common Stock   (2) 9/15/2017     M    33026   A $1.96   1587709   D    
Common Stock   9/15/2017     S    54833   D $2.90   1532876   D    
Common Stock   9/18/2017     S    6000   D $2.85   1526876   D    
Common Stock   (3) 9/19/2017     M    13661   A $2.01   1540537   D    
Common Stock   9/19/2017     S    24516   D $2.75   1516022   D    
Common Stock   9/20/2017     M    25000   A $2.26   1541022   D    
Common Stock   (4) 9/20/2017     M    34265   A $2.43   1575286   D    
Common Stock   9/20/2017     S    65405   D $2.75   (5) 1509881   D    
Common Stock   9/21/2017     S    619   D $2.75   1509262   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options   $1.78   9/15/2017     M         45421    2/9/2013   2/9/2022   Common Stock   45421   $0.00   0   D    
Options   (2) $1.96   9/15/2017     M         33026    2/15/2013   2/15/2022   Common Stock   33026   $0.00   0   D    
Options   (3) $2.01   9/19/2017     M         13661    7/24/2009   7/24/2018   Common Stock   6902   $0.00   0   D    
Options   $2.26   9/20/2017     M         25000    7/21/2011   7/21/2020   Common Stock   25000   $0.00   0   D    
Options   (4) $2.43   9/20/2017     M         34265    7/21/2011   7/21/2020   Common Stock   34265   $0.00   0   D    

Explanation of Responses:
(1)  On September 14, 2017, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.95 per share. The highest sale price for the Common Stock was $2.98 per share and the lowest sale price was $2.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(2)  The options exercised were acquired from September 15, 2017 to September 19, 2017.
(3)  The options exercised were acquired from September 19, 2017 to September 20, 2017.
(4)  The options exercised were acquired from September 20, 2017 to September 21, 2017.
(5)  On September 20, 2017, the Reporting Person sold an aggregate of 65,405 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.78 per share and the lowest sale price was $2.75 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:
The Form 4 was due on September 18, 2017 but filed on September 22, 2017 to accommodate multiple connected transactions over several days all on one concise Form 4.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sirgo Mark A
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVENUE, SUITE 225
RALEIGH, NC 27612 		X
President and CEO

Signatures
/s/ Mark A. Sirgo 9/22/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioDelivery Sciences Charts.
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioDelivery Sciences Charts.